Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.

19 Wall Street research analysts have issued 12 month price objectives for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's share price to reach $243.72 in the next year. This suggests a possible upside of 8.2% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.

Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. Since then, ALNY stock has decreased by 5.2% and is now trading at $225.22.
View the best growth stocks for 2023 here.

Alnylam Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totaling 5,680,000 shares, an increase of 11.2% from the December 31st total of 5,110,000 shares. Based on an average daily trading volume, of 783,400 shares, the short-interest ratio is currently 7.3 days.
View Alnylam Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALNY earnings forecast.

Alnylam Pharmaceuticals will be holding an earnings conference call on Thursday, February 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.51) by $0.21. The biopharmaceutical company earned $187.63 million during the quarter, compared to analysts' expectations of $218.69 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 430.74% and a negative net margin of 123.02%. Alnylam Pharmaceuticals's revenue for the quarter was up 49.1% on a year-over-year basis. During the same period last year, the company posted ($2.18) earnings per share.

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.65%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), New York State Common Retirement Fund (0.13%), Tobam (0.09%), DekaBank Deutsche Girozentrale (0.07%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Indrani Lall Franchini, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $225.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $27.71 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($9.77) on an earnings per share basis.

The company employs 1,665 workers across the globe.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.